Irinotecan
Glypican-3 (GPC3)-Positive Squamous Non-small Cell Lung Cancer
BeOne MedicinesSmall moleculePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Glypican-3 (GPC3)-Positive Squamous Non-small Cell Lung Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
(+)-VINCRISTINE Pfizer | Phase 2 | B |
Bgb-B2033 BeOne Medicines | Phase 1 | CC |
Same molecule, other indications
Irinotecan is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →